NCT05382364 2026-03-12
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT06239467 2025-09-09
PIKture-01
OnKure, Inc.
Phase 1 Recruiting
NCT05868226 2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1 Recruiting
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT06162559 2024-01-11
TRAIN-4
The Netherlands Cancer Institute
Phase 1 Recruiting
NCT03846583 2020-10-23
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT01983501 2020-09-21
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Seagen Inc.
Phase 1 Completed
NCT02025192 2020-06-04
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Seagen Inc.
Phase 1 Completed